Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × Other hematologic neoplasm × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Phase 1/2 Completed

26 enrolled 14 charts

BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

41 enrolled

BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors